Trial reportMedicine2020
Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.
Trial report in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07170475 (A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- A qPCR-based approach targeting the microbial gene markerJournal of Parkinson's disease · 2026Article
- The future of pharmaceuticals: Artificial intelligence in drug discovery and development.Journal of pharmaceutical analysis · 2025Review
- Xanthine Oxidoreductase: A Double-Edged Sword in Neurological Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Multifaceted role of inosine in complex diseases and human health.Nutrition reviews · 2025Review
- Implication of xanthine oxidoreductase in oxidative stress-related chronic diseases.Frontiers in endocrinology · 2025Review
- Uric acid and alterations of purine recycling disorders in Parkinson's disease: a cross-sectional study.NPJ Parkinson's disease · 2024Article
- Comprehensive blood metabolomics profiling of Parkinson's disease reveals coordinated alterations in xanthine metabolism.NPJ Parkinson's disease · 2024Article
- Parkinson's Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges.International journal of molecular sciences · 2024Review
- Serum factors mediate changes in mitochondrial bioenergetics associated with diet and exercise interventions.GeroScience · 2024Article
- Brain network and energy imbalance in Parkinson's disease: linking ATP reduction andFrontiers in molecular neuroscience · 2024Review
- Could Alzheimer's disease be a maladaptation of an evolutionary survival pathway mediated by intracerebral fructose and uric acid metabolism?The American journal of clinical nutrition · 2023Review
- Uric Acid and Chronic Kidney Disease: Still More to Do.Kidney international reports · 2023Review
- Uric Acid in Parkinson's Disease: What Is the Connection?Movement disorders : official journal of the Movement Disorder Society · 2022Review
- Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.Molecules (Basel, Switzerland) · 2022Review
- Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review.Neurotoxicity research · 2022Review
- Inosine: A bioactive metabolite with multimodal actions in human diseases.Frontiers in pharmacology · 2022Review
- Characteristics of Neural Network Changes in Normal Aging and Early Dementia.Frontiers in aging neuroscience · 2021Review
- Genes, the brain, and artificial intelligence in evolution.Journal of human genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCellular energetics play an important role in Parkinsons disease etiology, but no treatments directly address this deficiency. Our past research showed that treatment with febuxostat and inosine increased blood hypoxanthine and ATP in healthy adults, and a preliminary trial in 3 Parkinson's disease patients suggested some symptomatic improvements with no adverse effects.
methodsTo examine the efficacy on symptoms and safety in a larger group of Parkinsons disease patients, we conducted a single-arm, open-label trial at 5 Japanese neurology clinics and enrolled thirty patients (nmales = 11; nfemales = 19); 26 patients completed the study (nmales = 10; nfemales = 16). Each patient was administered febuxostat 20 mg and inosine 500 mg twice-per-day (after breakfast and dinner) for 8 weeks. The primary endpoint was the difference of MDS-UPDRS Part III score immediately before and after 57 days of treatment.
resultsSerum hypoxanthine concentrations were raised significantly after treatment (Pre = 11.4 μM; Post = 38.1 μM; P < .0001). MDS-UPDRS Part III score was significantly lower after treatment (Pre = 28.1 ± 9.3; Post = 24.7 ± 10.8; mean ± SD; P = .0146). Sixteen adverse events occurred in 13/29 (44.8%) patients, including 1 serious adverse event (fracture of the second lumbar vertebra) that was considered not related to the treatment.
conclusionsThe results of this study suggest that co-administration of febuxostat and inosine is relatively safe and effective for improving symptoms of Parkinsons disease patients. Further controlled trials need to be performed to confirm the symptomatic improvement and to examine the disease-modifying effect in long-term trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.